AI assistant
Celldex Therapeutics, Inc. — Director's Dealing 2024
Jun 3, 2024
31801_dirs_2024-06-03_3ddc4936-ba42-48a7-ac7a-b446fcdc9cf5.zip
Director's Dealing
Open in viewerOpens in your device viewer
SEC Form 4 — Statement of Changes in Beneficial Ownership
Issuer: Celldex Therapeutics, Inc. (CLDX)
CIK: 0000744218
Period of Report: 2024-05-30
Reporting Person: Crowley Elizabeth (N/A)
Non-Derivative Transactions
| Date | Security | Code | Shares | Price | A/D | Holdings After | Ownership |
|---|---|---|---|---|---|---|---|
| 2024-05-30 | Common Stock | M | 34445 | $2.78 | Acquired | 39171 | Direct |
| 2024-05-30 | Common Stock | M | 8500 | $9.0165 | Acquired | 47671 | Direct |
| 2024-05-30 | Common Stock | S | 38597 | $33.6395 | Disposed | 9074 | Direct |
Derivative Transactions
| Date | Security | Exercise Price | Code | Shares | A/D | Expiration | Underlying | Ownership |
|---|---|---|---|---|---|---|---|---|
| 2024-05-30 | Incentive Stock Option (Right to Buy) | $2.78 | M | 34445 | Disposed | 2029-06-19 | Common Stock (34445) | Direct |
| 2024-05-30 | Incentive Stock Option (Right to Buy) | $9.0165 | M | 8500 | Disposed | 2028-06-13 | Common Stock (8500) | Direct |
Footnotes
F1: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $33.39 to $33.8934 per share, inclusive. The reporting person undertakes to provide to Celldex Therapeutics, Inc., any security holder of Celldex Therapeutics, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth herein.
F2: As of June 19, 2023, the option is fully vested.
F3: As of June 13, 2022, the option is fully vested.